Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | IAPP | P10997 | 4/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 3/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678566 | 1.00 | ESR1 (0.48) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL28249242 | 0.87 | ESR1 (0.49) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL2394180 | 0.87 | ESR1 (0.51) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL6855197 | 0.86 | CA1 (0.47) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL2865033 | 0.86 | CA1 (0.47) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL2388955 | 0.85 | ESR1 (0.47) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL26046327 | 0.85 | CA1 (0.49) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL2392659 | 0.84 | ESR1 (0.46) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL18900158 | 0.83 | CA1 (0.47) | ESR1CA1CA2CA4NFKB1 | |
| SCHEMBL6063979 | 0.83 | TYR (0.55) | NFKB1ALDH1A1MEN1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040261198-A1 | Restructuring and finishing of keratin fibers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2004-12-30 | — | — | US | claimed |
| EP-1455736-A1 | RESTRUCTURING AND FINISHING OF KERATIN FIBERS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-09-15 | — | — | EP | claimed |
| WO-2003053375-A1 | RESTRUCTURING AND FINISHING OF KERATIN FIBERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-07-03 | — | — | WO | claimed |
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3137074-B1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | UNIV EMORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2020-03-19 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180318315-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | disclosed |
| US-10052332-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3137074-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | Emory University (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| WO-2015167825-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20040261198-A1 | Restructuring and finishing of keratin fibers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2004-12-30 | — | — | US | disclosed |
| US-6541038-B1 | Impregnating wood with metal-containing treating agent containing lignin and/or lignin derivatives and a metal, a metal compound, and/or a metal ion, and oxidizing and/or macromolecularizing the lignin | SDS BIOTECH K.K. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1034903-A1 | METHOD FOR THE TREATMENT OF WOOD WITH METALLIC TREATMENT AND WOOD TREATED BY THE METHOD | Showa Denko Kabushiki Kaisha (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | ESR1 195/4885CA1 2176/4885CA2 1833/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
| US-10052332-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
| US-20180318315-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | ESR1 226/4885CA1 1806/4885CA2 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.